Head-to-head evidence
Oxcarbazepine (Trileptal) vs Rufinamide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: Voltage-gated sodium channel · full Epilepsy pipeline
Oxcarbazepine (Trileptal)
Marketed by Novartis
NCT00050934 · Phase 3 · completed
The study enrolled 132 participants and measured the clinical outcome of seizure-frequency change, but the registry does not document randomization, blinding, or a comparator arm. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Rufinamide
Marketed by Eisai and partners
NCT00334958 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial with 356 participants, and its primary clinical endpoint was change in partial-seizure frequency. The reported median change favored rufinamide (-23.25% versus -9.80% with placebo), but the registry does not state whether this primary comparison was statistically significant, so the result remains unclear.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Oxcarbazepine (Trileptal)'s landscape · Rufinamide's landscape